Public Comment on the Use of Blood-based Biomarkers for Alzheimer’s Disease in Specialty Care Settings Clinical Practice Guideline

The comment period is now closed. The guideline panel, Association staff and guideline team will review all submitted comments and incorporate feedback appropriately. All comments will be posted online publicly upon guideline publication in July 2025. No personal identifying information will be included with comments; however, if comments were submitted on behalf of an organization or institution, this will be noted. If you have any questions or comments, please contact Malavika Tampi, Director, Clinical Practice Guidelines, at mptampi@alz.org.

First Name *

Last Name *

Title and affiliation: *

Which best describes you:*

Country *

E-mail Address

Question/Comment *

By providing this information and clicking the "Submit" button, you acknowledge and consent to the terms of the Association's Privacy Policy.